Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ZYUS Life SciencesZLSCF Cash Ratio is 0.01 as of Mar. 2026, which is 83% below its 10-year median of 0.06. The stock has 7 warning signs investors should review. Among 973 Drug Manufacturers companies, ZYUS Life Sciences ranks worse than 97.33% on this metric.
ZYUS Life Sciences has a Cash Ratio of 0.01. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for ZYUS Life Sciences's Cash Ratio or its related term are showing as below:
ZLSCF'
s Cash Ratio Range Over the Past 10 Years
Min: 0.01 Med: 0.06 Max: 1.03
Current: 0.01
During the past 5 years, ZYUS Life Sciences's highest Cash Ratio was 1.03. The lowest was 0.01. And the median was 0.06.
ZLSCF's Cash Ratio is ranked worse than 97.33% of 973
companies
in the Drug Manufacturers industry
Industry Median: 0.6
vs ZLSCF: 0.01
ZYUS Life Sciences (OTCPK:ZLSCF) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
ZYUS Life Sciences Cash Ratio Related Terms
ZYUS Life Sciences Cash Ratio Historical Data
* Premium members only.
The historical data trend for ZYUS Life Sciences's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, ZYUS Life Sciences's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ZYUS Life Sciences Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ZYUS Life Sciences's Cash Ratio distribution charts can be found below:
* The bar in red indicates where ZYUS Life Sciences's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZYUS Life Sciences (ZLSCF) has a Cash Ratio of 0.01 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on ZYUS Life Sciences and its competitors. This is 83% below median its historical median of 0.06. Over the past decade, ZYUS Life Sciences' Cash Ratio has ranged from 0.01 to 1.03. According to the industry distribution chart, ZYUS Life Sciences ranks #947 out of 973 companies in the Drug Manufacturers industry, placing it in the top 97.3%.
Is ZYUS Life Sciences' Cash Ratio too high?
ZYUS Life Sciences' current Cash Ratio of 0.01 is 83% below median its 10-year median of 0.06. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 1.03. The Drug Manufacturers industry median Cash Ratio is 0.60. ZYUS Life Sciences' value of 0.01 is 98.3% below this industry median. Based on the distribution chart, ZYUS Life Sciences ranks #947 out of 973 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does ZYUS Life Sciences' Cash Ratio compare to RMTI and BTAI?
According to the Drug Manufacturers industry distribution chart, ZYUS Life Sciences ranks #947 out of 973 companies for Cash Ratio. This places ZYUS Life Sciences in the lower half of its industry. The industry median Cash Ratio is 0.60. ZYUS Life Sciences' value of 0.01 is 98.3% below this benchmark. Historically, ZYUS Life Sciences' own Cash Ratio has ranged from 0.01 to 1.03 over the past decade. While the company's 10-year median is 0.06 vs. the industry median of 0.60, ZYUS Life Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.60, based on 973 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ZYUS Life Sciences's current Cash Ratio of 0.01 is 98.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on ZYUS Life Sciences and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ZYUS Life Sciences's current Cash Ratio is 0.01, which is 83% below median its own 10-year median of 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ZYUS Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, ZYUS Life Sciences (ZLSCF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.60, compared to a current price of $0.01 — trading 97.7% below its estimated fair value. The current Cash Ratio is 0.01, which is 83% below median its 10-year median of 0.06 and 98.3% below the Drug Manufacturers industry median of 0.60. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For ZYUS Life Sciences (ZLSCF), the current Cash Ratio is 0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ZYUS Life Sciences Corp is primarily engaged in the world-wide development and commercialization of cannabinoid-based therapeutics and product candidates. It is a licensed producer and distributor of medical cannabis for both medical and adult recreational access in Canada. The company has one reportable segment: Bio-pharmaceutical Products (including medical cannabis derivatives). Geographically, it operates in Canada; United States; Australia; and European Union.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLSCF has been successfully added to your 
